Bio-Path Holdings (BPTH) Misses Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Bio-Path Holdings Reports First Quarter 2016 Financial Results
May 11, 2016 7:30 AM EDTHOUSTON, May 11, 2016 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the first quarter ended March 31, 2016 and also provided an update on recent corporate developments.
2016 is already proving to be a truly pivotal year for Bio-Path as we advanced our clinical programs and further validated our DNAbilize technology with two important research collaborations, said Peter Nielsen, President and CEO of Bio-Path Holdings. We were pleased to... More
